SCHEMBL3206028

SCHEMBL3206028

CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)OCCl

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.51
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 1/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
KLK7 P49862 1/20 0.47
LMNA P02545 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
EPHX2 P34913 1/20 0.46
KDM4E B2RXH2 1/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
FKBP1A P62942 2/20 0.45
UCHL1 P09936 1/20 0.45
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4962228 1.00 HSD17B10 (0.54) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL23484492 0.96 FKBP1A (0.50) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL1401256 0.88 FKBP1A (0.58) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL440340 0.88 FKBP1A (0.58) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL8223617 0.88 FKBP1A (0.58) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL9933626 0.87 HSD17B10 (0.53) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL25960270 0.87 HSD17B10 (0.53) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL9933627 0.87 HSD17B10 (0.53) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL7286305 0.86 HSD17B10 (0.61) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A
SCHEMBL19414808 0.86 HSD17B10 (0.61) HSD17B10SMN1; SMN2ALDH1A1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070276-A Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same 人类生物科学股份有限公司 2026-05-19 CN disclosed
EP-4705289-A1 PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF Terran Biosciences Inc. (US) 2026-03-11 EP disclosed
WO-2024226691-A1 PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. (US) 2024-10-31 WO disclosed
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. 2024-02-29 US disclosed
EP-4041735-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS Biohaven Therapeutics Ltd. (US) 2022-08-17 EP disclosed
US-7674912-B2 Pro-drugs of N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2010-03-09 US disclosed
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA2B, ADORA1 HSD17B10 4188/4885SMN1; SMN2 1680/4885ALDH1A1 727/4885
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS MPO, CAT, SOD1 HSD17B10 992/4885SMN1; SMN2 80/4885ALDH1A1 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.